Swiss-based, formerly Bruker AG - split on the 5th October 2001 into the groups: Bruker Daltonics (Mass spectroscopy), Bruker Optics (Infrared spectroscopy), Bruker AXS (X-ray spectroscopy) and Bruker BioSpin (The largest part, the NMR business core, the EPR and the Tomography activities).
Product Lines:

[This entry is marked for removal.]

(July 20, 2009 - EPIX Pharmaceuticals, Inc. announced today that, in light of the company's lack of capital and inability to obtain additional financing or consummate a strategic transaction, it has entered into an Assignment for the Benefit of Creditors, effective immediately, in accordance with Massachusetts law).
EPIX has been a specialty pharmaceutical firm developing targeted contrast agents to improve the capability of MRI as a diagnostic tool for a variety of diseases. Gadofosveset trisodium (formerly MS-325, Vasovistâ„¢, now ABLAVARtâ„¢), is an injectable intravascular contrast agents designed for multiple vascular imaging applications, including peripheral vascular disease and coronary artery disease. EPIX conducted a pivotal Phase III trial for the detection of peripheral vascular disease, as well as a Phase II feasibility trial for coronary artery disease diagnosis.
To ensure rapid development and adoption of gadofosveset trisodium into clinical practice upon regulatory approval, EPIX pursued an aggressive product development plan and commercialization strategy. The Company established an exclusive, worldwide sales and marketing agreement with Bayer Schering Pharma AG. EPIX also established corporate collaborations with GE Healthcare, Philips Medical Systems and Siemens Medical Systems, the three leading MRI manufacturers, which together account for approximately 80 percent of the MRI machines installed worldwide.
EPIX had other MRI contrast agents under development, most significantly a novel prototype blood clot agent (EP-2104R). Potential clinical applications for this type of agent include detection of deep venous thrombosis, pulmonary embolism and blood clots in the coronary and carotid arteries. Currently, there is no high resolution imaging technique to directly visualize blood clots in patients with suspected cardiovascular disease.

Founded in 1969, Elscint is headquartered in Haifa, Israel. Elscint developed advanced computerized imaging systems in Computed Tomography (CT), Magnetic Resonance Imaging (MRI), Nuclear Medicine (NM) and Mammography (MAM) for international markets.
In November 1998, General Electric Medical Systems (GEMS) acquired the Nuclear Medicine and MRI divisions of Elscint, including an unique MRI gradient system concept and technology (twin gradient system).
Elscint Ltd. signs definitive agreement to sell its Nuclear Medicine and Magnetic Resonance Imaging Businesses for $100 Million. Elscint's shareholders approved the sale of its NM, and MRI division to GE (now GE Healthcare). Picker International acquires the Computed Tomography Division of Elscint Ltd. in the same year.

See also Marconi Medical Systems.

(fMRI) Functional magnetic resonance imaging is a technique used to determine the dynamic brain function, often based on echo planar imaging, but can also be performed by using contrast agents and observing their first pass effects through brain tissue. Functional magnetic resonance imaging allows insights in a dysfunctional brain as well as into the basic workings of the brain.
The in functional brain MRI most frequently used effect to assess brain function is the blood oxygenation level dependent contrast (BOLD) effect, in which differential changes in brain perfusion and their resultant effect on the regional distribution of oxy- to deoxyhaemoglobin are observable because of the different 'intrinsic contrast media' effects of the two haemoglobin forms. Increased brain activity causes an increased demand for oxygen, and the vascular system actually overcompensates for this, increasing the amount of oxygenated haemoglobin. Because deoxygenated haemoglobin attenuates the MR signal, the vascular response leads to a signal increase that is related to the neural activity.
Functional imaging relates body function or thought to specific locations where the neural activity is taking place. The brain is scanned at low resolution but at a fast rate (typically once every 2-3 seconds). Structural MRI together with fMRI provides an anatomical baseline and best spatial resolution.
Interactions can also be seen from the motor cortex to the cerebellum or basal ganglia in the case of a movement disorder such as ataxia. For example: by a finger movement the briefly increase in the blood circulation of the appropriate part of the brain controlling that movement, can be measured.

MRI hardware includes the electrical and mechanical components of a scanning device.
The main hardware components for the MRI machine are:
The magnet establishing the B0 field to align the spins.
Within the magnet are the gradient coils for producing variations in B0 in the X, Y, and Z directions to make a localization of the received data possible.
Within the gradient coil or directly on the object being imaged is the radio frequency (RF) coil. This RF coil is used to establish the B1 magnetic field necessary to excite the spinning nuclei. The RF coil also detects the signal emitted from the spins within the object being imaged.
The RF amplifier increases the power of the pulses.
The analog to digital converter converts the received analog raw data into digital values.
Depending on the design of the device and the body part being imaged the patient is positioned inside the magnet (e.g. on a movable table or standing upright).
The MRI scan room is surrounded by a RF shield (Faraday cage).
In addition, a computer console, a display, and a film printer belong to the MRI equipment.

See also the related poll result: 'Most outages of your scanning system are caused by failure of'